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Abstract
The DNA mismatch repair (MMR) pathway is responsible for the repair of base–base mismatches and insertion/
deletion loops that arise during DNA replication. MMR deﬁciency is currently estimated to be present in 15–17% of
colorectal cancer cases and 30% of endometrial cancers. MLH1 is one of the key proteins involved in the MMR
pathway. Inhibition of a number of mitochondrial genes, including POLG and PINK1 can induce synthetic lethality in
MLH1-deﬁcient cells. Here we demonstrate for the ﬁrst time that loss of MLH1 is associated with a deregulated
mitochondrial metabolism, with reduced basal oxygen consumption rate and reduced spare respiratory capacity.
Furthermore, MLH1-deﬁcient cells display a signiﬁcant reduction in activity of the respiratory chain Complex I. As a
functional consequence of this perturbed mitochondrial metabolism, MLH1-deﬁcient cells have a reduced anti-oxidant
response and show increased sensitivity to reactive oxidative species (ROS)-inducing drugs. Taken together, our results
provide evidence for an intrinsic mitochondrial dysfunction in MLH1-deﬁcient cells and a requirement for MLH1 in the
regulation of mitochondrial function.
Introduction
When the genes that mediate the DNA mismatch repair
(MMR) pathway, such as MLH1, MSH2 and MSH6, are
mutated or epigenetically silenced, the predisposition to
cancer is vastly increased1. In particular, germline muta-
tions in the MMR genes MLH1 and MSH2 predispose to
Lynch syndrome2. MMR deﬁciency is present in numer-
ous tumour types including colorectal and endometrial
cancers1,3,4. Speciﬁcally, MLH1 expression is lost in
8–21% of colorectal cancers5–7 and 24–37% of endo-
metrial cancers4,8,9.
Mitochondria are essential organelles in all eukaryotic
cells that mediate cellular energy (adenosine triphosphate
(ATP)) production via oxidative phosphorylation. During
this process, electrons are transferred through a series of
oxidative phosphorylation complexes known as the elec-
tron transport chain (ETC) in which a proton gradient is
produced across the inner mitochondrial membrane to
form an electrochemical membrane potential10. This
membrane potential is then used by the F0F1 ATP syn-
thase to generate ATP. Importantly, mitochondria are
also major sites of reactive oxidative species (ROS) pro-
duction. Therefore, unsurprisingly mitochondrial dys-
function is detrimental to the cell. For example, ROS
produced via accidental escape of electrons from
the oxidative phosphorylation complexes I and III can
induce oxidative damage to lipids, proteins and DNA11.
Indeed, mitochondrial dysfunction is implicated in the
pathology of numerous diseases including cancer.
Although the main role of the MMR pathway is the repair
of DNA replication errors, there is evidence that it
has several non-canonical roles, including participating
in homologous recombination, mitotic and meiotic
© The Author(s) 2019
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Sarah A. Martin (sarah.martin@qmul.ac.uk)
1Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University
of London, Charterhouse Square, London EC1M 6BQ, UK
2Department of Cell and Developmental Biology, Consortium for
Mitochondrial Research, University College London, London WC1E 6BT, UK
Full list of author information is available at the end of the article
These authors contributed equally: Sukaina Rashid, Marta O. Freitas
Edited by G.M. Liccardi
Ofﬁcial journal of the Cell Death Differentiation Association
12
34
56
78
90
()
:,;
12
34
56
78
90
()
:,;
1
2
3
4
5
6
7
8
9
0
()
:,;
12
34
56
78
90
()
:,;
recombination, and in the repair of oxidative DNA
damage12–14. More recently, a role has been suggested for
MLH1 in the mitochondria. We and others have pre-
viously shown that MLH1 can localise to the mitochon-
dria and inhibition of a number of mitochondrial genes,
including POLG and PINK1, can induce synthetic leth-
ality in MLH1-deﬁcient cells14–17. This synthetic lethal
interaction was associated with an increase in oxidative
DNA lesions (8-oxoG) in the mitochondrial DNA
(mtDNA).
mtDNA is particularly prone to oxidative DNA damage
for a variety of reasons, including its close proximity to
the ETC where the majority of ROS is generated and the
fact that it is not protected by histones18. It is estimated
that the levels of oxidative damage in the mitochondria
are two to three times higher than in nuclear DNA19,20. It
has been established that mitochondria utilise base exci-
sion repair as their primary mechanism for repairing
mitochondrial oxidative DNA damage21. Nevertheless,
there is increasing evidence that some form of MMR
machinery is present in the mitochondria and that MMR
proteins are potentially also involved in the repair of
oxidative DNA damage to mtDNA22–24.
Herein, we provide evidence that MLH1 is required for
the maintenance of mitochondria function. We elucidate
how targeting mitochondrial function may be a novel
therapeutic approach for the treatment of MLH1-
deﬁcient disease.
Results
MLH1 loss is associated with decreased mitochondrial
bioenergetics
Our previous studies have suggested that inhibition of a
number of mitochondrial genes is synthetically lethal with
MLH1 loss14,17. Therefore, we hypothesised that mito-
chondrial function may be altered in MLH1-deﬁcient
cells. To investigate this further, we determined initially
whether mitochondrial bioenergetics are deregulated in
MLH1-deﬁcient cells. To this end, we analysed oxygen
consumption rates (OCR) and the extracellular acidiﬁca-
tion rate (ECAR) in the MLH1-deﬁcient colorectal cancer
cell line, HCT116 and the isogenically matched MLH1-
proﬁcient, HCT116+ chr3 cells, using the Seahorse
XtraFlux (XF) analyser. The XF analyser measures the rate
of oxygen consumption in a given sample providing a
measure of oxidative phosphorylation. The basal OCR
represents a measure of basal oxidative phosphorylation
and upon addition of the uncoupling agent, carbonyl
cyanide-p-triﬂuoromethoxyphenylhydrazone (FCCP), a
measure of the cells maximal respiratory capacity is esti-
mated. When the basal OCR is subtracted from the
maximal respiration, a measure of spare respiratory
capacity (SRC) is obtained. The SRC reﬂects the cells
ability to respond to stress and increased energy demands.
Interestingly, we observed a decrease in the basal OCR
(Fig. 1a, b; p < 0.05) and a decrease in the SRC (Fig. 1c; p <
0.05) in the MLH1-deﬁcient cells compared to the MLH1-
proﬁcient cells. To determine whether these differences
were speciﬁc to the HCT116 isogenic colorectal cancer
cell lines, we measured the basal OCR of a panel of
MLH1-proﬁcient and MLH1-deﬁcient cell lines from a
range of different tumour types and a range of different
genetic backgrounds. We observed a decrease in the basal
OCR upon loss of MLH1 regardless of tumour cell type
(Fig. 1d). The impact of MLH1 loss on glycolysis was
determined by analysing the ECAR of the surrounding
media, by measuring the excretion of lactic acid per unit
time after its conversion from pyruvate. No signiﬁcant
difference was observed in the ECAR in the MLH1-
deﬁcient colorectal cancer cell line, HCT116 in compar-
ison to the isogenically matched MLH1-proﬁcient,
HCT116+ chr3 cells (Fig. 1e). Taken together, our results
show for the ﬁrst time that MLH1 loss is associated with
decreased oxidative phosphorylation and with a reduced
capacity to respond to increased energy demands.
Decreased Complex I activity in MLH1-deﬁcient cells
To investigate further the decreased oxidative phos-
phorylation observed in our panel of MLH1-deﬁcient
cells, we assessed the expression levels of the ﬁve oxida-
tive phosphorylation complexes in our cells. We observed
decreased expression of Complex I, in the MLH1-
deﬁcient HCT116 cell line in comparison to the MLH1-
proﬁcient cell line HCT116+ chr3 (Fig. 2a; Supplemen-
tary Fig. 1A; p < 0.0005). We further validated our
observation by analysing Complex I expression in the
MLH1-proﬁcient endometrial cancer cell line KLE,
transfected with either Control, non-targeting siRNA or
siRNA targeting MLH1 (Fig. 2b; Supplementary Fig. 1B; p
< 0.05). Complex I expression was also reduced upon
MLH1 silencing. To determine whether this reduction
was speciﬁc to the accessory subunit NDUFB8 measured
or Complex I in general, we analysed gene expression of
the mitochondrial-encoded Complex I subunits MTND2
and MTND5 (Fig. 2c; *p < 0.05, **p < 0.005). Our data
demonstrate that expression of MTND2 and MTND5
were also decreased in the HCT116 MLH1-deﬁcient cells,
in comparison to the MLH1-proﬁcient cells. To further
investigate Complex I in the absence of MLH1 expression,
we next measured whether MLH1 expression is required
for Complex I activity. Complex I activity was measured
using an ELISA assay assessing the oxidation of NADH to
NAD+. Interestingly, we observed a decrease in the
activity of Complex I in the MLH1-deﬁcient cell line
HCT116, compared to the MLH1 proﬁcient HCT116+
chr3 cells (Fig. 2d; p < 0.0005). To ensure this reduction
was not speciﬁc to HCT116 cells, we analysed Complex I
activity upon MLH1 silencing in the MLH1-proﬁcient
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KLE cells (Fig. 2e; p < 0.05). We also observed a reduction
in Complex I activity upon MLH1 silencing. In addition,
we analysed Complex I activity in our diverse panel of
MLH1-deﬁcient and -proﬁcient cells and observed a sta-
tistically signiﬁcant decrease in the activity of Complex I
upon MLH1 loss across all cell lines (Supplementary Fig.
1C). Our results suggested that oxidative phosphorylation
was impaired in MLH1-deﬁcient cells due to decreased
Complex I activity. Previous studies have reported that
colorectal cancer cells can have increased mutations
within microsatellites in mitochondrial-encoded Complex
I genes23. It is widely known that MLH1-deﬁcient cells
have increased nuclear microsatellite instability (MSI),
therefore we hypothesised that perhaps the deregulated
OCR and abrogated Complex I activity, we observe in our
MLH1-deﬁcient cells may be due to MSI in
mitochondrial-encoded Complex I genes. To elucidate
this further, we carried out next-generation sequencing
(NGS) on the mitochondrial genome of the HCT116 and
HCT116+ chr3 cells, using the Illumina MiSeq platform.
Interestingly we did not observe any differences in
mutations within the seven known mitochondrial-
encoded Complex I genes as well as the non-coding D-
loop regions, which are known to harbour mutations
affecting Complex I (Supplementary Table 1). We only
identiﬁed one coding mutation, which was in the MLH1-
proﬁcient cells in MT-CO1 gene at a very low frequency
(~26%). However, it is of note that the NGS analysis we
performed was limited with regards to MSI detection, and
therefore our MSI analysis was inconclusive. We next
Fig. 1 MLH1 loss is associated with decreased oxygen consumption rate and reduced spare respiratory capacity. The Seahorse Bioscience
XF24 extracellular ﬂux analyser was used to measure OCR (pMoles/min), indicative of OXPHOS in MLH1-deﬁcient HCT116 cell line and the MLH1-
proﬁcient HCT116+ chr3 cell line. a After establishing a baseline, oligomycin (1 μM), FCCP (0.25 μM), rotenone (1 μM) and antimycin (1 μm) were
sequentially added, as indicated by arrows. b The basal OCR was calculated using the difference between the mean of time points in baseline and in
oligomycin treatment (baseline minus oligomycin OCR). c The spare respiratory capacity was calculated as (OCR following FCCP—baseline OCR). d
The basal OCR was lower in a panel of MLH1-deﬁcient cell lines (HCT116, SKOV3, IGROV, AN3CA, MFE-296, SW48 and A2780cp70) compared to the
MLH1-proﬁcient cell lines (HCT116+ chr3, HT29, SW620 and A2780). e After establishing a baseline, glucose (10 mM), oligomycin (1 μM) and 2-DG
(50mM) were sequentially added, as indicated by arrows. b–d Experiments were carried out in triplicate and error bars represent standard error of
the mean (SEM). *p < 0.05
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Fig. 2 Reduced Complex I activity in MLH1-deﬁcient cells. a Western blot analysis of MLH1-deﬁcient HCT116 and MLH1-proﬁcient HCT116+ chr3
cells. Protein was extracted and expression was analysed using anti-Total OXPHOS, anti-MLH1 and β-actin antibodies. β-actin is used as a loading
control. b Western blot analysis of MLH1-proﬁcient KLE cells transfected with either non-targeting control siRNA (siCtrl) or siRNA targeting MLH1
(siMLH1). Protein was extracted and expression was analysed using anti-Complex I (accessory subunit NDUFB8), anti-MLH1 and β-actin antibodies.
β-actin is used as a loading control. c Quantitative RT-PCR analysis of RNA extracted from HCT116 and HCT116+ chr3 cells. mRNA expression was
measured using ND2, ND5 and β-actin Taqman probes. β-actin was used as a control. Complex I activity was measured using an ELISA assay. Protein
lysates were isolated from the d MLH1-deﬁcient HCT116 and MLH1-proﬁcient HCT116+ chr3 cell lines and e KLE cells transfected with either siControl
or siRNA targeting MLH1. Equal amounts of protein were incubated to determine the activity of Complex I by measuring the oxidation of NADH to
NAD+ and the simultaneous reduction of a dye leading to increased absorbance at 450 nm, over time. f Reduced mtDNA copy number in MLH1-
deﬁcient cells. Relative mtDNA copy number expressed as a ratio of total genomic DNA in MLH1-deﬁcient HCT116 and MLH1-proﬁcient HCT116+ chr3
cells. g Analysis of data from 619 colorectal adenocarcinoma patient samples. Mutations in MLH1 and NDUFA9, as represented using OncoPrint
analysis from cBioPortal, where each bar is representative of a tumour that contains a mutation. Aligned bars represent the same tumour. Green lines
represent missense mutations, orange lines represent in frame mutations, black lines represent known truncating mutations (putative driver mutations)
and grey lines represent known truncating mutations (putative passenger mutations). The incidence of MLH1 mutation was 4%, whilst the incidence of
NDUFA9 mutation was 1.8% in the 619 patient samples. NDUF9A was mutated in 17.39% of MLH1 mutated cases, in comparison to 1.17% of MLH1
wild-type cases. All experiments were carried out in triplicate and error bars represent the SEM. *p < 0.05, **p < 0.005. See also Fig. S1A–C
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looked at mitochondrial copy number in the MLH1-
deﬁcient and -proﬁcient cells by determining the ratio of
the mitochondrial tRNA gene, relative to the nuclear
housekeeping gene, β2M. Interestingly, there was a
striking decrease in the mitochondrial copy number upon
MLH1 loss (Fig. 2f). Our data suggest that in the absence
of MLH1, replication of mtDNA is impaired.
Mutations in the Complex I subunit NDUFA9 signiﬁcantly
co-occur with MLH1 mutations in colorectal
adenocarcinoma patients
Our results indicate that Complex I activity is perturbed
in our panel of cell lines from a range of tumour types. We
next investigated if similar Complex I dysfunction was
also observed in MLH1-deﬁcient patient tumour samples.
To this end, we interrogated the whole exome sequencing
data from 619 cases of colorectal adenocarcinoma
patients25 using the cBioPortal tool (www.cbioportal.org).
We observed that the Complex I subunit NDUFA9 was
mutated in 17.39% ofMLH1 mutated cases in comparison
to 1.17% of MLH1 wild-type cases (Fig. 2g; Table 1). This
ﬁnding indicates that there is a signiﬁcant co-occurrence
(p= 0.00004) of MLH1 loss and NDUFA9 mutations in
colorectal adenocarcinoma patients, therefore supporting
our in vitro data.
Reduced expression of mitochondrial biogenesis and anti-
oxidant defence genes in MLH1-deﬁcient cells
Our results thus far have described a mitochondrial
phenotype in MLH1-deﬁcient cell lines, with deﬁciencies
in Complex I, decreased oxidative phosphorylation and
reduced mtDNA copy number. Therefore, we next
investigated whether mitochondrial biogenesis, in general
was attenuated upon MLH1 loss. To this end, we exam-
ined the expression of the nuclear transcriptional co-
activator PGC-1β in the MLH1-deﬁcient and -proﬁcient
cell lines, since PGC-1β is known as the master regulator
of mitochondrial biogenesis26. We observed a decrease in
the expression of PGC-1β mRNA in the MLH1-deﬁcient
HCT116 cell line (Fig. 3a; p < 0.005) and upon MLH1-
silencing in the MLH1-proﬁcient KLE cells (Fig. 3b; p <
0.005). We have previously shown that increased oxidative
DNA damage to mtDNA is synthetically lethal with
MLH1 deﬁciency14,17. A recent study has shown that
reduced levels of the antioxidant response protein, NRF2
can lead to decreased Complex I levels27. Given our
observations that Complex I activity is reduced upon
MLH1 loss and MLH1-deﬁcient cells are sensitive to
increased oxidative DNA damage, we hypothesised that
loss of MLH1 was associated with a reduced antioxidant
response. To elucidate this, we analysed whether expres-
sion of proteins involved in the antioxidant response were
altered in the absence of MLH1 expression. NRF2 is the
key transcription factor and master regulator of the
antioxidant defence pathway. It detects signals activated
due to cellular oxidative stress and activates downstream
genes including glutathione peroxidase 1 (GPX1). To
determine whether our MLH1-deﬁcient cells have an
aberrant antioxidant response, we measured the expres-
sion of the antioxidant response genes NRF2 and GPX1 in
our MLH1-deﬁcient and -proﬁcient cells and upon
MLH1 silencing in the MLH1-proﬁcient KLE cells.
Interestingly, we observed a decrease in expression at
both the RNA (Fig. 3c, d; **p < 0.005, ***p < 0.0005) and
protein (Fig. 3e) level. To further investigate this, we
measured the activity of GPX1 in the MLH1-proﬁcient
KLE cells transfected with either siControl or siRNA
targeting MLH1 (Fig. 3f). We observed a reduction in
GPX1 activity upon MLH1 silencing.
Taken together, our data suggest that MLH1-deﬁcient
cells have a broad rearrangement of mitochondrial gene
expression including decreased mitochondrial biogenesis
and anti-oxidant response genes, leading to a dysfunc-
tional mitochondrial phenotype.
MLH1 loss results in increased sensitivity to the Complex I
inhibitor, Rotenone
Our results suggest that expression of the anti-oxidant
response genes, NRF2 and GPX1 are reduced in MLH1-
deﬁcient cells. Given that MLH1 loss gives rise to a
reduced antioxidant response, we investigated whether
this attenuated response resulted in sensitivity to
increased oxidative stress. To this end, we ﬁrst treated the
HCT116 and HCT116+ chr3 cells with the ROS-inducing
agent Parthenolide (Fig. 4a, b). It has been previously
shown that Parthenolide activates NADPH oxidase and
causes oxidative stress by inducing ROS28. We observed
that the MLH1-deﬁcient HCT116 cells were more sensi-
tive to Parthenolide treatment, in comparison to the
MLH1-proﬁcient HCT116+ chr3 cells (Fig. 4b). In addi-
tion, we observed that silencing of MLH1 sensitised the
MLH1-proﬁcient KLE cells to Parthenolide treatment
Table 1 Signiﬁcant co-occurrence of MLH1 and NDUFA9 mutations identiﬁed upon whole exome sequencing of 619
colon adenocarcinoma patient samples (25)
Gene Cytoband Percentage of alteration (MLH1 mut) Percentage of alteration (MLH1 wt) Log ratio p Value q Value Tendency
NDUFA9 12p13.32 4 (17.39%) 7 (1.17%) 3.89 4.05E-04 0.0251 Co-occurrence
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(Fig. 4c). To determine whether it was oxidative stress
that was causing this selectivity, we treated our cell lines
with increasing concentrations of Parthenolide, in addi-
tion to the ROS scavenging agent N-acetyl-cysteine
(NAC; Fig. 4d). Addition of NAC rescued the selectivity
observed with Parthenolide treatment in MLH1-deﬁcient
cells, therefore suggesting that it is oxidative stress that
results in the reduced cell viability in HCT116 cells upon
Parthenolide treatment. To further assess the generality of
our observations, we examined Parthenolide sensitivity in
a panel of MLH1 deﬁcient and proﬁcient tumour cell lines
(Supplementary Fig. 1B). Although MLH1 mutations are
not the only genetic variable within this diverse tumour
cell panel, we observed a clear distinction in Parthenolide
sensitivity between tumour lines with wild‐type MLH1
expression and those with MLH1 deﬁciency. We also
observed increased sensitivity of MLH1-deﬁcient cells to
the ROS-inducing, Complex I inhibitor, Rotenone (Fig.
4e). Our results therefore suggest that the decreased
ability of MLH1-deﬁcient cells to respond to oxidative
stress has uncovered a vulnerability that may be exploited
therapeutically by ROS-inducing agents.
Taken together, our data indicates that impaired
Complex I activity and a subsequent perturbed anti-
oxidant stress response is responsible for the sensitivity of
MLH1-deﬁcient cells to increased oxidative stress (illu-
strated in Fig. 5).
Discussion
Here, we show for the ﬁrst time a novel role for MLH1
in maintaining functional mitochondria. Given the dual
function of MLH1 in repair of DNA replication errors and
mitochondria biogenesis, it is inherently difﬁcult to dis-
sect a separate impact of these two roles upon tumour-
igenesis. The mutator phenotype is clearly the driving
force behind carcinogenesis in many MMR-deﬁcient
Fig. 3 MLH1 loss is associated with reduced mitochondrial gene expression. Quantitative RT-PCR analysis of RNA extracted from a HCT116 and
HCT116+ chr3 cells or b KLE cells transfected with either siCTRL siRNA targeting MLH1. mRNA expression was measured using PGC1β and β-actin
Taqman probes. β-actin was used as a control. Quantitative RT-PCR analysis of RNA extracted from c HCT116 and HCT116+ chr3 cells or d KLE cells
transfected with either siCTRL or siRNA targeting MLH1. mRNA expression was measured using MLH1, NRF2, GPX1 and β-actin Taqman probes.
β-actin was used as a control. e Western blot analysis of MLH1-deﬁcient HCT116 and MLH1-proﬁcient HCT116+ chr3 cells. Protein was extracted and
expression was analysed using antibodies as indicated. β-actin is used as a loading control. f GPX1 activity was measured using a commercially
available GPX1 activity assay. Protein lysates were isolated from the KLE cells transfected with either siControl or siRNA targeting MLH1. Equal
amounts of protein were incubated to determine the activity of GPX1 by measuring the optical density for NADPH at 340 nm before and after
addition of cumene hydroperoxide (substrate for GPX1)
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tumours but does impaired mitochondrial metabolism
also contribute, either via increased oxidative mtDNA
damage or independently? A number of studies have
examined the speciﬁc role of oxidative damage repair by
the MMR pathway in relation to tumourigenesis. Colussi
et al.29 demonstrated that a decrease in 8-oxoG levels
translated into a decrease in the MMR-mediated mutator
effect, by expressing MTH1 in MSH2-deﬁcient mouse
embryonic ﬁbroblasts. In addition, treating MLH1-
deﬁcient cells in the presence of the antioxidant ascor-
bate, with and without H2O2 treatment, reduced mutation
rates and reduced MSI by 30%30. However, studies have
also suggested that MLH1 deﬁcient, HCT116 cells are less
sensitive to H2O2 than their MMR proﬁcient counterparts
(HCT116+ chr3)30,31. We have previously shown that
MSH2-deﬁcient cells are more sensitive to treatment with
H2O2
32. Furthermore, treatment with the ROS-inducing
agent, potassium bromate in an Msh2−/− mice, increased
the formation of epithelial tumours in the small intes-
tine33. The evidence thus far suggests that the MMR
system may suppress carcinogenesis in the context of
oxidative damage by directly repairing ROS-induced DNA
lesions or acting as a sensor of oxidative damage, thereby
activating apoptosis.
Loss of the MMR pathway is currently estimated to
occur in approximately 30% of endometrial tumours. Loss
of MMR has been associated with high tumour grade and
metastasis in endometrial cancer34. Here, we show for the
Fig. 4 MLH1 loss is associated with increased ROS and sensitivity upon Parthenolide treatment. a Increased ROS levels in MLH1-deﬁcient cells
upon Parthenolide treatment. The HCT116 and HCT116+ chr3 cells were treated with either DMSO or Parthenolide (10 μM) for 30 min. Cells were
washed and treated with 10 µM DHE, and ﬂuorescence was measured on the MitoXpress ﬂuorescent microscope as a measure of ROS production. b
HCT116 and HCT116+ chr3 cells or c KLE cells transfected with either siControl or siRNA targeting MLH1, were treated with increasing concentrations
of the Parthenolide. After 4 days treatment, cell viability was measured using an ATP-based luminescence assay. d The HCT116 and HCT116+ chr3
cells were treated with increasing concentrations of the Parthenolide, in the presence or absence of N-acetyl cysteine (NAC). After 4 days treatment,
cell viability was measured using an ATP-based luminescence assay. e KLE cells transfected with either siControl or siRNA targeting MLH1, were
treated with increasing concentrations of the Rotenone. After 4 days treatment, cell viability was measured using Alamar Blue. All experiments were
carried out in triplicate and error bars represent the SEM. *p < 0.05, **p < 0.005, ***p < 0.0005. See also Fig. S1D
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ﬁrst time that loss of MLH1 results in reduced OCR,
reduced Complex I activity, and increased reactive oxygen
species. Previously, it has been shown that mtDNA
mutations that resulted in reduced Complex I activity and
increased ROS enhanced the metastatic potential of
tumour cells35. Given that loss of MMR is a key feature of
metastasis in endometrial cancer, it would be interesting
to understand whether the mitochondrial phenotype
driven by MLH1 loss gives rise to the increased metastasis
in MMR-deﬁcient endometrial cancer.
The DNA repair protein Ataxia-telangiectasia (ATM) is
recruited to sites of DNA damage resulting in DNA
repair, apoptosis or cell cycle arrest36,37. There is emer-
ging evidence that the phenotype observed in ataxia-
telangiectasia is unlikely to be solely related to the nuclear
DNA repair functions of ATM and that ATM has a role in
the mitochondria. Studies have shown that A–T
lymphoblastoid cells (ATM-deﬁcient) have dysfunctional
mitochondria compared to wild-type cells as evidenced by
abnormal mitochondrial structure, reduced mitochondrial
membrane potential and decreased mitochondrial
respiration38. In addition, ATM-deﬁcient thymocytes
have swollen mitochondria with abnormal cristae in
addition to increased mitochondrial ROS and decreased
Complex I activity39. ATM signalling has been shown to
be involved in the regulation of ribonucleotide reductase
(RR), the rate-limiting enzyme essential for the synthesis
of deoxyribonucleoside triphosphates and mitochondrial
homoeostasis, and therefore ATM is required for the
control of mtDNA copy number in response to oxidative
DNA damage40. ATM-deﬁcient cells have lower levels of
NAD+ due to the persistent unrepaired DNA damage
thus these cells have a reduced antioxidant capacity and
increased ROS levels41. It is well established that when the
MMR pathway is recruited to sites of DNA damage,
MLH1 can associate with ATM in recruiting other com-
ponents of the DNA damage response pathway42.
Therefore, the role of MLH1 in maintaining mitochon-
drial function may be in part associated with ATM. It may
be possible that the interaction of ATM with MLH1 is
required to maintain mitochondrial homoeostasis.
Taken together, we have elucidated a vulnerability in
MLH1-deﬁcient tumour cells such that due to dysfunc-
tional mitochondria, these cells have a reduced anti-
oxidant response. Collectively, our data suggest that this
decrease in the antioxidant response and deregulated
mitochondrial metabolism drives sensitivity to the Com-
plex I inhibitor Rotenone, in MLH1-deﬁcient cells and
can be exploited clinically.
Experimental procedures
Cell culture
The human colon cancer cell line HCT116 and
HCT116+ chr3 were a kind gift from Dr. Alan Clark
(NIEHS). The human ovarian cancer cell lines A2780,
A2780cp70, SKOV3 and IGROV were a kind gift from Dr.
Michelle Lockley (QMUL). The human endometrial
cancer cell lines, KLE, MFE-296 and AN3CA, and the
human colon cancer cell lines, HT29 and SW48 were
purchased from ATCC. All cell lines were grown in
DMEM (Sigma-Aldrich), 10% foetal calf serum (FBS;
Invitrogen) and 100 U/ml penicillin and 100 µg/ml
streptomycin at 37 °C/5% CO2 apart from SKOV and
IGROV which were routinely grown in RPMI-1640 media
(Sigma) supplemented with 10% FBS and 100 U/ml
penicillin and 100 µg/ml streptomycin at 37 °C/5% CO2.
All cell lines were authenticated on the basis of short
tandem repeat-proﬁle, viability, morphologic inspection,
and were routinely mycoplasma tested. Parthenolide and
Rotenone were purchased from Sigma-Aldrich. NAC was
purchased from Santa Cruz.
Fig. 5 Schematic illustration of mitochondrial dysfunction and
subsequent increased sensitivity to Parthenolide in MLH1-
deﬁcient cells. MLH1-deﬁcient cells display a reduced mtDNA copy
number, dysfunctional Complex I activity and a reduced anti-oxidant
stress response leading to the sensitivity of MLH1-deﬁcient cells to
increased oxidative stress
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Cell viability assays
Cells were seeded in 96-well plates (1–2 × 103 cells/well)
24 h before treatment with increasing concentrations of
Rotenone or Parthenolide. After 5 days, cell viability was
assessed using either CellTiter Glo (Promega) or Alamar
Blue (Invitrogen).
Western blot
Cells were lysed in 20mM Tris (pH 8), 200 mM NaCl,
1 mM EDTA, 0.5% (v/v) NP40, 10% glycerol, supple-
mented with protease inhibitors (Roche). Equivalent
amounts of protein were electrophoresed on 4–12%
Novex precast gels (Invitrogen) and transferred to nitro-
cellulose membrane. After blocking for 1 h in 1×TBS/5%
non-fat dried milk, membranes were incubated overnight
at 4 °C in primary antibody, including anti-MLH1 (#4256,
Cell Signalling), anti-Total OXPHOS Human Antibody
Cocktail (Ab110411, Abcam), anti-NRF2 (Ab137550,
Abcam), anti-GPX1 (#3286, Cell Signalling) and anti-
β-actin-HRP (#4970, Cell Signalling). Membranes were
incubated with anti-IgG-horseradish peroxidase and
visualised by chemiluminescent detection (Supersignal
West Pico Chemiluminescent Substrate, Pierce). Immu-
noblotting for β-Actin was performed as a loading
control.
Real-time quantitative PCR (qRT-PCR)
RNA was extracted from cells using an RNeasy kit
(Qiagen) and quantiﬁed using a Nanodrop spectro-
photometer (Thermo). The Omniscript cDNA synthesis
kit (Qiagen) was used to reverse transcribe 500 ng of RNA
and 1 µl cDNA was used in each quantitative polymerase
chain reaction (PCR) reaction. Multiplex PCR was per-
formed on the ABI Prism 7500 Real-Time PCR Instru-
ment (Applied Biosystems) and the δδCt method was
used for data analysis. Taqman probes for each indicated
target were purchased from Applied Biosystems (Life
Technologies).
siRNA transfections
For siRNA transfections, KLE cells were transfected
with an MLH1 siRNA (Qiagen) using Lipofectamine
RNAiMax (Invitrogen) according to the manufacturer’s
instructions. As a control for each experiment, cells were
transfected with a non-targeting control siRNA and
concurrently analysed.
Complex I activity
Complex I activity was measured using the Complex I
activity ELISA assay (ab109721, Abcam), according to
manufacturer’s instructions. Samples were added to a
microplate pre-coated with capture antibodies speciﬁc to
Complex I. After the target was immobilised, Complex I
activity was determined following the oxidation of NADH
to NAD+ and the simultaneous reduction of the provided
dye, which leads to increased absorbance at OD 450 nm.
GPX1 activity
GPX1 activity was measured using the GPX1 activity
assay (ab102530, Abcam), according to manufacturer’s
instructions. Samples were washed with PBS, resuspended
in Assay Buffer, homogenised and centrifuged for 15 min
at 10,000g at 4 °C. Assay plates were set up with super-
natants and standards. NADPH, glutathione reductase
and glutathione solutions were added to samples for
15min to deplete all glutathione disulphide. Optical
density for NADPH at 340 nm was measured before and
after addition of cumene hydroperoxide (substrate
for GPX1).
Seahorse extracellular ﬂux analyser
OCR, ECAR and SRC were measured using the Sea-
horse extracellular ﬂux analyser (Seahorse Bioscience). A
calibration plate (Seahorse Bioscience) containing a sen-
sor cartridge with ports to allow addition of drugs was
placed on top of a calibration plate, which was hydrated
by adding 1ml of calibrant solution (Seahorse Bioscience)
to each well of the calibrant plate. Cells were seeded in XF
24-well or 96-well cell culture microplates (Seahorse
Bioscience) and incubated for 24 h, growth media was
removed from each well and replaced with 500 µl of assay
medium (pH 7.4) pre-warmed to 37 °C. The cells were
incubated at 37 °C for a least 60 min in a non-CO2 incu-
bator to allow media temperature and pH to reach equi-
librium before the ﬁrst rate measurement. Prior to each
rate measurement, the XF24 or XF96 Analyser gently
mixed the assay media in each well to allow the oxygen
partial pressure to reach equilibrium. Following mixing,
OCR was measured to establish a baseline rate. The assay
medium was then gently mixed again between each rate
measurement to restore normal oxygen tension and pH in
the microenvironment surrounding the cells. Uncoupled,
maximal and non-mitochondrial respiration was deter-
mined after the addition of oligomycin (1 μM), FCCP
(0.25 μM), rotenone (1 μM) and antimycin (1 μm). ECAR
was determined after the addition of glucose (10 mM),
oligomycin (1 μM) and 2-DG (50mM). All chemicals
were purchased from Sigma.
ROS analysis
ROS levels were measured by high content ﬂuorescence
imaging, using the ImageXpress Micro XL (Molecular
Devices) instrument. Cells were plated in a 96-well black/
clear bottom plate (BD Falcon) and after 24 h treated with
either DMSO or Parthenolide (1 µM) and incubated for
30min at 5% CO2. Cells were then incubated with dihy-
droethidium (DHE), (Invitrogen, 10 µM). Cytosolic DHE
exhibits blue ﬂuorescence and upon reaction with
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superoxide anions, becomes oxidised to 2-hydro-
xyethidium, intercalates with DNA, and exhibits a red
ﬂuorescence (excitation/emission 530/380 (nm))43. The
rate of the increase in ﬂurescence, which reﬂects probe
oxidation was measured in the same number of sites and
cells per well using the ImageXpress instrument. Each
experiment was carried out in triplicate and a ratio
between the ﬂuorescence values at 530 and 380 nm were
calculated for each sample and data plotted is the average
increased ratio rate.
mtDNA copy number quantiﬁcation
The measurement of mtDNA copy number, relative to
nuclear DNA copy number was determined by amplifying
mitochondrial tRNA-Leu(UUR) and nuclear-encoded
β2m (beta-2-microglobulin) genes. Total DNA was
extracted using the QIAmp DNA mini kit (Qiagen, Hil-
den, Germany), according to the manufacturer’s instruc-
tions. RT PCR reactions were performed on a
LightCycler® 480 RT PCR Instrument (Roche Diagnostic).
Totally, 2 μl of total DNA (3 ng/μl) and primer pairs in a
total volume of 25 μl, were added to Light Cycler®
480SYBR Green I Master Mix (Roche Diagnostics).
Human β2m forward (5′-TGCTGTCTCCATGTTT-
GATGTATC T-3′) and β2m reverse (5′-TCTCTGCT
CCCCACCTCTAAGT-3′) or tRNA-Leu(UUR) forward
(5′-CACCCAAGAACAGGGTTTGT-3′) and tRNA-Leu
(UUR) reverse (5′-TGGCCATGGGTATGTTGTTA-3′)
primers were used. The following protocol was used:
50 °C for 2 min, 95 °C for 10min, 40 cycles of 95 °C for
15 s and 62 °C for 60 s. A dissociation curve was also
calculated for each sample to ensure presence of a single-
PCR product. To determine the mtDNA content, relative
to nuclear DNA the following equations were used: ΔCT
= (nucDNA CT−mtDNA CT); relative mtDNA content
= 2 × 2ΔCT.
mtDNA sequencing
Total DNA extraction was carried out for each cell
line in triplicate, using the QIAamp DNA extraction kit
(Qiagen) according to the manufacturer’s instruction.
mtDNA was ampliﬁed in two overlapping fragments
using the MTL-1 (9065 bp) and MTL-2 primers
(11170 bp; Illumina) with high-ﬁdelity Takara LA Taq
(Clontech). Reactions were performed in duplicate.
DNA products were checked for the correct size and
quantiﬁed for subsequent normalisation to 0.2 ng/μL
using a 2200 TapeStation instrument (Agilent). Dual
indexed libraries were generated from 1 ng of PCR
products using Nextera XT library preparation tech-
nology (Illumina) and sequenced on the Illumina MiSeq
v2 platform, according to the manufacturer’s recom-
mendations. The MiSeq re-sequencing protocol for
small genome sequencing was followed according to the
manufacturer’s recommendations. On-board software
(i.e., Real-TimeAnalysis and MiSeq Reporter) converted
raw data to Binary Alignment/Map and Variant Call
Format v4.1 ﬁles using Genome Analysis Toolkit. The
sequenced region of interest was aligned to the revised
Cambridge Reference Sequence. Each nucleotide posi-
tion was interrogated and variations from the reference
were annotated by base difference. The median
sequencing depth was 9261×.
Statistical analysis
Unless stated otherwise, data represent standard error of
the mean of at least three independent experiments. The
two-tailed paired Student’s t test was used to determine
statistical signiﬁcance with p < 0.05 regarded as signiﬁcant.
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